Banks - Regional
Compare Stocks
5 / 10Stock Comparison
CARE vs UVSP vs NBTB vs MNSB vs IBCP
Revenue, margins, valuation, and 5-year total return — side by side.
Banks - Regional
Banks - Regional
Banks - Regional
Banks - Regional
CARE vs UVSP vs NBTB vs MNSB vs IBCP — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | |||||
|---|---|---|---|---|---|
| Industry | Banks - Regional | Banks - Regional | Banks - Regional | Banks - Regional | Banks - Regional |
| Market Cap | $580M | $1.10B | $2.35B | $176M | $699M |
| Revenue (TTM) | $255M | $518M | $867M | $136M | $315M |
| Net Income (TTM) | $31M | $91M | $169M | $16M | $69M |
| Gross Margin | 61.7% | 61.0% | 72.1% | 54.4% | 69.6% |
| Operating Margin | 15.7% | 21.9% | 25.3% | 14.0% | 25.8% |
| Forward P/E | 4.8x | 11.1x | 10.8x | 10.4x | 9.6x |
| Total Debt | $179M | $352M | $327M | $70M | $117M |
| Cash & Equiv. | $105M | $554M | $185M | $25M | $52M |
CARE vs UVSP vs NBTB vs MNSB vs IBCP — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| Carter Bankshares, … (CARE) | 100 | 371.0 | +271.0% |
| Univest Financial C… (UVSP) | 100 | 234.7 | +134.7% |
| NBT Bancorp Inc. (NBTB) | 100 | 143.9 | +43.9% |
| MainStreet Bancshar… (MNSB) | 100 | 177.2 | +77.2% |
| Independent Bank Co… (IBCP) | 100 | 245.7 | +145.7% |
Price return only. Dividends and distributions are not included.
Quick Verdict: CARE vs UVSP vs NBTB vs MNSB vs IBCP
Each card shows where this stock fits in a portfolio — not just who wins on paper.
CARE carries the broadest edge in this set and is the clearest fit for growth exposure.
- Rev growth 6.2%, EPS growth 32.1%
- Lower P/E (4.8x vs 10.8x)
- Beta 0.56 vs UVSP's 1.01
- +69.0% vs NBTB's +9.0%
UVSP is the #2 pick in this set and the best alternative if valuation efficiency is your priority.
- PEG 0.76 vs IBCP's 1.82
- Efficiency ratio 0.4% vs NBTB's 0.5% (lower = leaner)
- Efficiency ratio 0.4% vs NBTB's 0.5%
NBTB ranks third and is worth considering specifically for income & stability.
- Dividend streak 12 yrs, beta 0.89, yield 3.2%
- 10.4% NII/revenue growth vs MNSB's -1.4%
- 3.2% yield, 12-year raise streak, vs UVSP's 2.3%, (2 stocks pay no dividend)
MNSB lags the leaders in this set but could rank higher in a more targeted comparison.
IBCP is the clearest fit if your priority is long-term compounding and sleep-well-at-night.
- 184.6% 10Y total return vs UVSP's 140.1%
- Lower volatility, beta 0.83, Low D/E 23.2%, current ratio 370.62x
- Beta 0.83, yield 3.0%, current ratio 370.62x
- NIM 3.3% vs CARE's 2.7%
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 10.4% NII/revenue growth vs MNSB's -1.4% | |
| Value | Lower P/E (4.8x vs 10.8x) | |
| Quality / Margins | Efficiency ratio 0.4% vs NBTB's 0.5% (lower = leaner) | |
| Stability / Safety | Beta 0.56 vs UVSP's 1.01 | |
| Dividends | 3.2% yield, 12-year raise streak, vs UVSP's 2.3%, (2 stocks pay no dividend) | |
| Momentum (1Y) | +69.0% vs NBTB's +9.0% | |
| Efficiency (ROA) | Efficiency ratio 0.4% vs NBTB's 0.5% |
CARE vs UVSP vs NBTB vs MNSB vs IBCP — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
CARE vs UVSP vs NBTB vs MNSB vs IBCP — Financial Metrics
Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.
Who Leads Where
IBCP leads in 1 of 6 categories
CARE leads 1 • NBTB leads 1 • UVSP leads 0 • MNSB leads 0 • 3 tied
Explore the data ↓Income & Cash Flow (Last 12 Months)
Evenly matched — NBTB and IBCP each lead in 2 of 5 comparable metrics.
Income & Cash Flow (Last 12 Months)
NBTB is the larger business by revenue, generating $867M annually — 6.4x MNSB's $136M. IBCP is the more profitable business, keeping 21.7% of every revenue dollar as net income compared to MNSB's 11.5%.
| Metric | |||||
|---|---|---|---|---|---|
| RevenueTrailing 12 months | $255M | $518M | $867M | $136M | $315M |
| EBITDAEarnings before interest/tax | $46M | $119M | $241M | $23M | $89M |
| Net IncomeAfter-tax profit | $31M | $91M | $169M | $16M | $69M |
| Free Cash FlowCash after capex | $30M | $92M | $225M | $13M | $70M |
| Gross MarginGross profit ÷ Revenue | +61.7% | +61.0% | +72.1% | +54.4% | +69.6% |
| Operating MarginEBIT ÷ Revenue | +15.7% | +21.9% | +25.3% | +14.0% | +25.8% |
| Net MarginNet income ÷ Revenue | +12.3% | +17.5% | +19.5% | +11.5% | +21.7% |
| FCF MarginFCF ÷ Revenue | +12.5% | +18.7% | +25.2% | +7.8% | +22.2% |
| Rev. Growth (YoY)Latest quarter vs prior year | — | — | — | — | — |
| EPS Growth (YoY)Latest quarter vs prior year | +8.3% | +23.1% | +39.5% | +120.9% | +2.3% |
Valuation Metrics
Evenly matched — UVSP and MNSB and IBCP each lead in 2 of 7 comparable metrics.
Valuation Metrics
At 10.4x trailing earnings, IBCP trades at a 45% valuation discount to CARE's 18.7x P/E. Adjusting for growth (PEG ratio), UVSP offers better value at 0.84x vs IBCP's 1.97x — a lower PEG means you pay less per unit of expected earnings growth.
| Metric | |||||
|---|---|---|---|---|---|
| Market CapShares × price | $580M | $1.1B | $2.4B | $176M | $699M |
| Enterprise ValueMkt cap + debt − cash | $654M | $897M | $2.5B | $221M | $764M |
| Trailing P/EPrice ÷ TTM EPS | 18.71x | 12.21x | 13.53x | 13.36x | 10.38x |
| Forward P/EPrice ÷ next-FY EPS est. | 4.77x | 11.10x | 10.80x | 10.45x | 9.56x |
| PEG RatioP/E ÷ EPS growth rate | — | 0.84x | 1.92x | — | 1.97x |
| EV / EBITDAEnterprise value multiple | 16.34x | 7.49x | 10.35x | 11.58x | 9.39x |
| Price / SalesMarket cap ÷ Revenue | 2.28x | 2.12x | 2.71x | 1.30x | 2.22x |
| Price / BookPrice ÷ Book value/share | 1.40x | 1.18x | 1.21x | 0.82x | 1.41x |
| Price / FCFMarket cap ÷ FCF | 18.25x | 11.34x | 10.75x | 16.57x | 9.96x |
Profitability & Efficiency
IBCP leads this category, winning 4 of 9 comparable metrics.
Profitability & Efficiency
IBCP delivers a 14.2% return on equity — every $100 of shareholder capital generates $14 in annual profit, vs $7 for MNSB. NBTB carries lower financial leverage with a 0.17x debt-to-equity ratio, signaling a more conservative balance sheet compared to CARE's 0.43x. On the Piotroski fundamental quality scale (0–9), CARE scores 8/9 vs MNSB's 5/9, reflecting strong financial health.
| Metric | |||||
|---|---|---|---|---|---|
| ROE (TTM)Return on equity | +7.6% | +9.8% | +9.5% | +7.3% | +14.2% |
| ROA (TTM)Return on assets | +0.7% | +1.1% | +1.1% | +0.7% | +1.3% |
| ROICReturn on invested capital | +5.7% | +6.5% | +7.9% | +5.0% | +10.2% |
| ROCEReturn on capital employed | +1.5% | +8.8% | +2.4% | +0.9% | +2.6% |
| Piotroski ScoreFundamental quality 0–9 | 8 | 7 | 7 | 5 | 8 |
| Debt / EquityFinancial leverage | 0.43x | 0.37x | 0.17x | 0.32x | 0.23x |
| Net DebtTotal debt minus cash | $73M | -$202M | $142M | $45M | $65M |
| Cash & Equiv.Liquid assets | $105M | $554M | $185M | $25M | $52M |
| Total DebtShort + long-term debt | $179M | $352M | $327M | $70M | $117M |
| Interest CoverageEBIT ÷ Interest expense | 0.39x | 0.60x | 1.05x | 0.31x | 0.91x |
Total Returns (Dividends Reinvested)
CARE leads this category, winning 3 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in CARE five years ago would be worth $18,721 today (with dividends reinvested), compared to $12,056 for MNSB. Over the past 12 months, CARE leads with a +69.0% total return vs NBTB's +9.0%. The 3-year compound annual growth rate (CAGR) favors UVSP at 33.4% vs MNSB's 6.7% — a key indicator of consistent wealth creation.
| Metric | |||||
|---|---|---|---|---|---|
| YTD ReturnYear-to-date | +34.8% | +20.9% | +9.3% | +19.4% | +7.2% |
| 1-Year ReturnPast 12 months | +69.0% | +32.0% | +9.0% | +26.4% | +12.6% |
| 3-Year ReturnCumulative with dividends | +94.7% | +137.1% | +54.1% | +21.5% | +130.6% |
| 5-Year ReturnCumulative with dividends | +87.2% | +46.4% | +29.9% | +20.6% | +63.7% |
| 10-Year ReturnCumulative with dividends | +112.9% | +140.1% | +102.2% | +126.9% | +184.6% |
| CAGR (3Y)Annualised 3-year return | +24.9% | +33.4% | +15.5% | +6.7% | +32.1% |
Risk & Volatility
Evenly matched — CARE and UVSP each lead in 1 of 2 comparable metrics.
Risk & Volatility
CARE is the less volatile stock with a 0.56 beta — it tends to amplify market swings less than UVSP's 1.01 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. UVSP currently trades 98.8% from its 52-week high vs IBCP's 90.8% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | |||||
|---|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.56x | 1.01x | 0.89x | 0.66x | 0.83x |
| 52-Week HighHighest price in past year | $26.58 | $39.06 | $46.92 | $25.17 | $37.39 |
| 52-Week LowLowest price in past year | $15.37 | $27.91 | $39.20 | $17.86 | $29.63 |
| % of 52W HighCurrent price vs 52-week peak | +98.5% | +98.8% | +96.1% | +93.4% | +90.8% |
| RSI (14)Momentum oscillator 0–100 | 75.4 | 68.1 | 57.3 | 50.4 | 50.6 |
| Avg Volume (50D)Average daily shares traded | 276K | 180K | 236K | 58K | 176K |
Analyst Outlook
NBTB leads this category, winning 2 of 2 comparable metrics.
Analyst Outlook
Analyst consensus: CARE as "Buy", UVSP as "Hold", NBTB as "Hold", MNSB as "Hold", IBCP as "Hold". Consensus price targets imply 11.9% upside for IBCP (target: $38) vs -11.9% for UVSP (target: $34). For income investors, NBTB offers the higher dividend yield at 3.17% vs UVSP's 2.28%.
| Metric | |||||
|---|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Hold | Hold | Hold | Hold |
| Price TargetConsensus 12-month target | $27.00 | $34.00 | $46.00 | — | $38.00 |
| # AnalystsCovering analysts | 4 | 6 | 10 | 1 | 7 |
| Dividend YieldAnnual dividend ÷ price | — | +2.3% | +3.2% | — | +3.0% |
| Dividend StreakConsecutive years of raises | 0 | 1 | 12 | 2 | 11 |
| Dividend / ShareAnnual DPS | — | $0.88 | $1.43 | — | $1.03 |
| Buyback YieldShare repurchases ÷ mkt cap | +3.4% | +3.2% | +0.4% | 0.0% | +1.8% |
IBCP leads in 1 of 6 categories (Profitability & Efficiency). CARE leads in 1 (Total Returns). 3 tied.
CARE vs UVSP vs NBTB vs MNSB vs IBCP: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is CARE or UVSP or NBTB or MNSB or IBCP a better buy right now?
For growth investors, NBT Bancorp Inc.
(NBTB) is the stronger pick with 10. 4% revenue growth year-over-year, versus -1. 4% for MainStreet Bancshares, Inc. (MNSB). Independent Bank Corporation (IBCP) offers the better valuation at 10. 4x trailing P/E (9. 6x forward), making it the more compelling value choice. Analysts rate Carter Bankshares, Inc. (CARE) a "Buy" — based on 4 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — CARE or UVSP or NBTB or MNSB or IBCP?
On trailing P/E, Independent Bank Corporation (IBCP) is the cheapest at 10.
4x versus Carter Bankshares, Inc. at 18. 7x. On forward P/E, Carter Bankshares, Inc. is actually cheaper at 4. 8x — notably different from the trailing picture, reflecting expected earnings growth. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: Univest Financial Corporation wins at 0. 76x versus Independent Bank Corporation's 1. 82x — a PEG below 1. 0 traditionally signals the market is underpricing earnings growth.
03Which is the better long-term investment — CARE or UVSP or NBTB or MNSB or IBCP?
Over the past 5 years, Carter Bankshares, Inc.
(CARE) delivered a total return of +87. 2%, compared to +20. 6% for MainStreet Bancshares, Inc. (MNSB). Over 10 years, the gap is even starker: IBCP returned +184. 6% versus NBTB's +102. 2%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — CARE or UVSP or NBTB or MNSB or IBCP?
By beta (market sensitivity over 5 years), Carter Bankshares, Inc.
(CARE) is the lower-risk stock at 0. 56β versus Univest Financial Corporation's 1. 01β — meaning UVSP is approximately 80% more volatile than CARE relative to the S&P 500. On balance sheet safety, NBT Bancorp Inc. (NBTB) carries a lower debt/equity ratio of 17% versus 43% for Carter Bankshares, Inc. — giving it more financial flexibility in a downturn.
05Which is growing faster — CARE or UVSP or NBTB or MNSB or IBCP?
By revenue growth (latest reported year), NBT Bancorp Inc.
(NBTB) is pulling ahead at 10. 4% versus -1. 4% for MainStreet Bancshares, Inc. (MNSB). On earnings-per-share growth, the picture is similar: MainStreet Bancshares, Inc. grew EPS 210. 0% year-over-year, compared to 3. 5% for Independent Bank Corporation. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — CARE or UVSP or NBTB or MNSB or IBCP?
Independent Bank Corporation (IBCP) is the more profitable company, earning 21.
7% net margin versus 11. 5% for MainStreet Bancshares, Inc. — meaning it keeps 21. 7% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: IBCP leads at 25. 8% versus 14. 0% for MNSB. At the gross margin level — before operating expenses — NBTB leads at 72. 1%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is CARE or UVSP or NBTB or MNSB or IBCP more undervalued right now?
The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.
By this metric, Univest Financial Corporation (UVSP) is the more undervalued stock at a PEG of 0. 76x versus Independent Bank Corporation's 1. 82x. A PEG below 1. 0 is traditionally considered the threshold for growth-adjusted undervaluation. On forward earnings alone, Carter Bankshares, Inc. (CARE) trades at 4. 8x forward P/E versus 11. 1x for Univest Financial Corporation — 6. 3x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for IBCP: 11. 9% to $38. 00.
08Which pays a better dividend — CARE or UVSP or NBTB or MNSB or IBCP?
In this comparison, NBTB (3.
2% yield), IBCP (3. 0% yield), UVSP (2. 3% yield) pay a dividend. CARE, MNSB do not pay a meaningful dividend and should not be held primarily for income.
09Is CARE or UVSP or NBTB or MNSB or IBCP better for a retirement portfolio?
For long-horizon retirement investors, Independent Bank Corporation (IBCP) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.
83), 3. 0% yield, +184. 6% 10Y return). Both have compounded well over 10 years (IBCP: +184. 6%, MNSB: +126. 9%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between CARE and UVSP and NBTB and MNSB and IBCP?
Both stocks operate in the Financial Services sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: CARE is a small-cap quality compounder stock; UVSP is a small-cap deep-value stock; NBTB is a small-cap deep-value stock; MNSB is a small-cap deep-value stock; IBCP is a small-cap deep-value stock. UVSP, NBTB, IBCP pay a dividend while CARE, MNSB do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.